Won - Figure 27
Medication Modification
FIG. 27: In addition to modifying medications to decrease the risk for CSA, as mentioned above, it should also be noted that new medications may affect SDB. A study by Farney et al[9] looked at the role of the opioid partial μ-agonist, buprenorphine (used for opioid dependency), and found that the risk for Op-CSA was not reduced by this medication. Thus, physicians should not be reassured when patients on chronic opioids transition to this class of medications.
Won C. Chest 2016;00.
References
[9]
Farney RJ, McDonald AM, Boyle KM, et al. Sleep disordered breathing in patients receiving therapy with buprenorphine/naloxone. Eur Respir J. 2013;42:394–403.
